目前接受基础胰岛素治疗的成人2型糖尿病患者（QWINT-3）：一项3期、随机、非劣效性试验：每周一次的α -胰岛素与每日一次的葡糖苷胰岛素对照

The Lancet Pub Date : 2025-06-22 DOI:10.1016/s0140-6736(25)01044-x

Prof Athena Philis-Tsimikas MD, Richard M Bergenstal MD, Timothy S Bailey MD, Hideaki Jinnouchi MD, James R Thrasher MD, Liza Ilag MD, Jit Mitra MS, Kristen Syring PhD, Rebecca J Threlkeld MS

{"title":"目前接受基础胰岛素治疗的成人2型糖尿病患者（QWINT-3）：一项3期、随机、非劣效性试验：每周一次的α -胰岛素与每日一次的葡糖苷胰岛素对照","authors":"Prof Athena Philis-Tsimikas MD, Richard M Bergenstal MD, Timothy S Bailey MD, Hideaki Jinnouchi MD, James R Thrasher MD, Liza Ilag MD, Jit Mitra MS, Kristen Syring PhD, Rebecca J Threlkeld MS","doi":"10.1016/s0140-6736(25)01044-x","DOIUrl":null,"url":null,"abstract":"Once-weekly insulin efsitora alfa (efsitora) is in development for the treatment of people with diabetes. The aim of the current study was to assess the efficacy and safety of once-weekly efsitora compared with daily insulin degludec (degludec) in adults with type 2 diabetes using basal insulin.","PeriodicalId":22898,"journal":{"name":"The Lancet","volume":"179 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial\",\"authors\":\"Prof Athena Philis-Tsimikas MD, Richard M Bergenstal MD, Timothy S Bailey MD, Hideaki Jinnouchi MD, James R Thrasher MD, Liza Ilag MD, Jit Mitra MS, Kristen Syring PhD, Rebecca J Threlkeld MS\",\"doi\":\"10.1016/s0140-6736(25)01044-x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Once-weekly insulin efsitora alfa (efsitora) is in development for the treatment of people with diabetes. The aim of the current study was to assess the efficacy and safety of once-weekly efsitora compared with daily insulin degludec (degludec) in adults with type 2 diabetes using basal insulin.\",\"PeriodicalId\":22898,\"journal\":{\"name\":\"The Lancet\",\"volume\":\"179 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-06-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Lancet\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/s0140-6736(25)01044-x\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Lancet","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/s0140-6736(25)01044-x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

每周一次的胰岛素efsitora alfa （efsitora）正在开发中，用于治疗糖尿病患者。目前研究的目的是评估每周一次的efsitora与每日一次的胰岛素降糖（degludec）对使用基础胰岛素的2型糖尿病成人患者的疗效和安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial

Once-weekly insulin efsitora alfa (efsitora) is in development for the treatment of people with diabetes. The aim of the current study was to assess the efficacy and safety of once-weekly efsitora compared with daily insulin degludec (degludec) in adults with type 2 diabetes using basal insulin.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

The Lancet

自引率

0.00%

发文量